Press releases
- Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
- Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
- Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
- Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
- Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
- Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
- Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
- Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
More ▼
Key statistics
On Friday, Syndax Pharmaceuticals Inc (1T3:DUS) closed at 17.60, -21.43% below its 52-week high of 22.40, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.40 |
---|---|
High | 17.70 |
Low | 17.40 |
Bid | 17.60 |
Offer | 17.90 |
Previous close | 18.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 84.99m |
Free float | 83.42m |
P/E (TTM) | -- |
Market cap | 1.64bn USD |
EPS (TTM) | -3.22 USD |
Data delayed at least 15 minutes, as of May 31 2024 18:30 BST.
More ▼